{"id":1015705,"date":"2026-10-30T08:17:07","date_gmt":"2026-10-30T12:17:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/"},"modified":"2026-10-30T08:17:07","modified_gmt":"2026-10-30T12:17:07","slug":"braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/","title":{"rendered":"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN FRANCISCO, Oct.  30, 2026  (GLOBE NEWSWIRE) &#8212; Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature remarks on Braveheart Bio&#8217;s cardiac myosin inhibitor program and the global clinical development of BHB-1893 in patients with obstructive HCM and non-obstructive HCM from Management and the following speakers:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">Anjali Owens, M.D., Associate Professor of Medicine and Medical Director, Penn Center for Inherited Cardiovascular Disease, Perelman School of Medicine at the University of Pennsylvania<\/li>\n<li style=\"margin-bottom:10pt\">Mariko Harper, M.D., Medical Director, Hypertrophic Cardiomyopathy Center of Excellence, Virginia Mason Franciscan Health\n<\/li>\n<\/ul>\n<p>A live question-and-answer session will follow the formal presentations.\u00a0<\/p>\n<p>Interested parties should register for the event at the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S8kjm7GYW13TU8Vzq02Q8aJgHxhfjhGYAQRnl4bpcloDs9kpjwPi-0abIIgtmvN9jAuGj2ETG2suS3ExTFl8Ag92fpUx98W1aPgkSOCaJeLQ2u_rFlagu0qJS1i0f6p_ufH7QdiLbi0m481UD4H0TLUfmItaK1HB7BTR7J1s36x-Dbg9JrKkTWmXPKM-mN5F3ZhliZTc9cV2yN-fDqNtEb0aHNyerUBmDq4FuSyJsTc=\" rel=\"nofollow\" target=\"_blank\">HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor<\/a>. A live webcast of the event will be accessible by visiting the Investor Relations section of the Braveheart Bio website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KyPJoHQd_uytVgK_6P8VlWuBZisN0wow-sFYsFd7wdWU0ME9pTBWVh3vvnurKIViqakRI4LOlGdsGIepNBtPCbfnsx5Z8-P88q7JMBojPSI=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.braveheart.bio\/<\/a>. A link to the webcast replay will be available in a temporary archive following the event.<\/p>\n<p>\n        <strong>About Braveheart Bio<\/strong>\n      <\/p>\n<p>Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio&#8217;s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7nrt2Ff8-yAKkqczE-QLKG4ohFUEHPXT2c5Z8Ea74oq_4Ac6-z6k87S7lhRQHA5NIpbbE2YlNxpnyKa-gTcC1Xwz792RT383yecH8fX6clg=\" rel=\"nofollow\" target=\"_blank\">www.braveheart.bio<\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact<br \/><\/strong>Alexander Sharif<br \/>New Street Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vZPOzIrY7HoESPan2E2--Rpv4-IgnRBeg_zv64q3pzIRsIExZGh3XGONwxqJim05nFvC_fBkJwJMfGe8cJJXNNO8uBU_g7wd1emmnNrXIZ5YXf9anbqXNH1MQexAH-71\" rel=\"nofollow\" target=\"_blank\">Alexander@NewStreetIR.com<\/a><\/p>\n<p>\n        <strong>Media Contact<br \/><\/strong>FGS Global<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=frKLC4v6jqK4j-5NohbkT1Jkul081ZxjecxUNkWopcCknOc357Feo91rqglyW52zpn1ixeC6OWlsaBz4i48THGk-7lmslPfF7WoUomzUCsjVCqgPK15xTyXNoJOP0lMv\" rel=\"nofollow\" target=\"_blank\">Braveheart-bio@fgsglobal.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWE0MTBjZWUtMWUzNC00OGQxLTg1MDYtNzM5MDZmNzc2ZGQxLTEzMjQxNDAtMjAyNi0xMC0zMC1lbg==\/tiny\/Braveheart-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) &#8212; Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature remarks on Braveheart Bio&#8217;s cardiac myosin inhibitor program and the global clinical development of BHB-1893 in patients with obstructive HCM and non-obstructive HCM from Management and the following speakers: Anjali Owens, M.D., Associate Professor of Medicine and Medical Director, Penn Center for Inherited Cardiovascular Disease, Perelman School of Medicine at the University of Pennsylvania Mariko Harper, M.D., Medical Director, Hypertrophic Cardiomyopathy Center of Excellence, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1015705","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) &#8212; Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature remarks on Braveheart Bio&#8217;s cardiac myosin inhibitor program and the global clinical development of BHB-1893 in patients with obstructive HCM and non-obstructive HCM from Management and the following speakers: Anjali Owens, M.D., Associate Professor of Medicine and Medical Director, Penn Center for Inherited Cardiovascular Disease, Perelman School of Medicine at the University of Pennsylvania Mariko Harper, M.D., Medical Director, Hypertrophic Cardiomyopathy Center of Excellence, &hellip; Continue reading &quot;Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-30T12:17:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026\",\"datePublished\":\"2026-10-30T12:17:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/\"},\"wordCount\":328,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/\",\"name\":\"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA=\",\"datePublished\":\"2026-10-30T12:17:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/","og_locale":"en_US","og_type":"article","og_title":"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026 - Market Newsdesk","og_description":"SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) &#8212; Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature remarks on Braveheart Bio&#8217;s cardiac myosin inhibitor program and the global clinical development of BHB-1893 in patients with obstructive HCM and non-obstructive HCM from Management and the following speakers: Anjali Owens, M.D., Associate Professor of Medicine and Medical Director, Penn Center for Inherited Cardiovascular Disease, Perelman School of Medicine at the University of Pennsylvania Mariko Harper, M.D., Medical Director, Hypertrophic Cardiomyopathy Center of Excellence, &hellip; Continue reading \"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-30T12:17:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026","datePublished":"2026-10-30T12:17:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/"},"wordCount":328,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/","name":"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA=","datePublished":"2026-10-30T12:17:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjczNSM3OTI1OTM5IzIzMTI1OTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/braveheart-bio-to-host-webinar-hcm-spotlight-advancing-a-next-generation-cardiac-myosin-inhibitor-with-key-opinion-leader-discussion-on-november-6-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Braveheart Bio to Host Webinar \u2013 HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor \u2013 with Key Opinion Leader Discussion on November 6, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1015705"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015705\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1015705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1015705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1015705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}